Execution Issues Continue To Undermine AngioDynamics Story (NASDAQ:ANGO)

4 mins read
54 views

There’s never been anything wrong, at least at the top level, with AngioDynamics’ (NASDAQ:ANGO) plan to pivot towards and refocus on higher-growth opportunities in the business like AngioVac, AlphaVac, Auryon, and NanoKnife and essentially “farm” the slower-growing legacy peripheral, vascular, and oncology/surgical businesses for cash

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

Swift confirmation of new ambassador to Israel uncertain as Senate Republicans attack his involvement in Iran nuclear deal

Next Story

Homebuilding bounced back in September

Latest from News